Navigation Links
Pharmos Corporation Reports 2009 Second Quarter Results
Date:8/12/2009

ed a decrease in interest expense of $79,784 as the decrease is attributable to reduced debenture interest. In the first half of 2009 the Company recorded $166,930 in interest expense related to the issuance of $4,000,000 in convertible debentures issued on January 3, 2008.

The company believes that the current cash and cash equivalents totaling $2.9 million as of June 30, 2009 will be sufficient to support the currently planned continuing operations through at least December 31, 2009. The Company routinely pursues various funding options, including additional equity offerings, equity-like financing, strategic corporate alliances, business combinations and the establishment of product related research and development limited partnerships, to obtain additional financing to continue the development of its products and bring them to commercial markets. On April 21, 2009, the Company completed a private placement of common stock and warrants. At the closing, the Company issued 18,000,000 shares of common stock and warrants exercisable for an additional 18,000,000 shares of common stock for an aggregate purchase price of $1,800,000. The exercise price of the warrants, which have a five-year term, is $0.12 per share. If the trial is successful, this financing would also support additional efforts to negotiate a strategic partnership or license arrangement with a pharmaceutical company. This is consistent with Pharmos' strategy as previously communicated, since the Company does not have the resources to continue to develop Dextofisopam through a Phase 3 trial.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextof
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Pharmos Restructures Operations in Israel
2. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
3. Pharmos Corporation Reports 2008 Third Quarter Results
4. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
5. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
6. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
7. Pharmos Completes Private Placement - Raises $1.8 Million
8. Pharmos Corporation Reports 2009 First Quarter Results
9. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
10. Brooke Franchise Corporation Announces Selected July Results
11. MedThink Communications Retained by NanoBio Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 Manhattan ... on the side of the hip , which could ... treatment in Manhattan. This treatment is now offered at New ... is also called trochanteric bursitis, occurs when the trochanteric ... fluid-filled sac in the hip, between the iliotibial band ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... are urging that all children aged 6 months and older ... Academy of Pediatrics updated their influenza vaccine recommendations to advise ... vaccine to build immunity. The AAP also wants parents of ... the nasal spray vaccine instead of the flu shot if ...
(Date:9/22/2014)... to 40 percent of patients undergoing breast cancer surgery ... all the cancerous tissue in the initial operation. However, ... tested a tool they developed that will help surgeons ... decreasing the chances for repeat operations. ... September 22, 2014 in the Proceedings of the ...
(Date:9/22/2014)... today became a founding partner in the Global STEM ... promoting young talent in science, technology, engineering and math ... York Academy of Sciences (NYAS), Malaysian Prime Minister Najib ... Sept. 22. , With the goal of developing over ... by 2020, the initiative will create a host of ...
(Date:9/22/2014)... living in Canada have a higher rate of heart ... while people, McMaster researchers have found. , The ... Association Journal (CMAJ Open) and may be found ... ethnic groups in the country is the more than ... about three percent of the population. They include people ...
Breaking Medicine News(10 mins):Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:The fine line between breast cancer and normal tissues 2Health News:Growing scientists: World's future jobs are rooted in STEM 2Health News:Growing scientists: World's future jobs are rooted in STEM 3Health News:Higher risk of heart disease for South Asians in Canada 2
... in need of blood or are you inclined in donating the ... way, the solution for it is just a few clicks away. ... amazingly useful venture in 2000. He works for Central Railway as ... venture too. ,If you're located in Kolkata and badly ...
... University immunologist and author of the study said that they have ... aim of the cure is to prevent the immune system before ... a window of time and the pancreatic cells can be rescued ... the disease. , The results were published in the ...
... of a suspected bird flu infection. After this incident ... shipments from out of town. ,The city ... for a final diagnosis of the case. Health authorities ... Her condition deteriorated quickly, and she died despite hospital ...
... the March of Dimes has shown that U.S pregnancy ... of 40 weeks//, which is a week shorter than ... the pregnancy term period is attributed to better capabilities ... assisted deliveries. As a result there are fewer stillbirths, ...
... Medical Center have found that teenagers who have used herbal ... and 15 times more likely to have // abused anabolic ... ,"The study points to the need for ... using herbal remedies and from there probe deeper for possible ...
... in China has revealed that just over 67 per cent ... ,This survey was conducted recently by a research institute at ... respondents in 24 colleges of 19 cities.,The results said that ... how HIV/AIDS is transmitted and 75.6 per cent know how ...
Cached Medicine News:Health News:New Network To Ease Blood donation In India 2Health News:Type 1 diabetes has a cure? 2Health News:Using Herbal Products Heightens Substance Abuse Risk in Teens 2
(Date:9/22/2014)... DUBLIN , Sept. 22, 2014 ... the "PCSK9 and Other Novel Hypercholesterolemia Drugs" ... indicate that there is a high cholesterol burden despite ... Out of all the available options, statins have been ... concluded that reduction of plasma LDL cholesterol (LDLC) is ...
(Date:9/22/2014)... 2014  Aethlon Medical, Inc. (OTCQB: AEMD), the ... infectious disease, cancer and other life-threatening conditions, disclosed ... (DARPA) has informed the Company that it plans ... four of a five-year $5.9 million contract that ... under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
(Date:9/22/2014)... , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... and fiscal 2014 ended July 31, 2014 on Monday, September ... to discuss the results at 11:00 AM ET. Participating in ... Andrew A. Krakauer , President and CEO; Jorgen ... A. Sheldon , Senior Vice President, CFO and Treasurer; and ...
Breaking Medicine Technology:PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2
... N.J., Oct. 15 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., has received approval from the United States ... Application (ANDA) for Amlodipine Besylate/Benazepril 5/20mg, 10/20mg, 2.5/10mg, and ... The ANDA was acquired as part of Watson,s acquisition ...
... Inc. (Nasdaq: REGN ) will webcast its ... Industry Conference on Friday, October 22, 2010.  The presentation ... may be accessed through the Company,s web site, ... version of the presentation will be available after the ...
Cached Medicine Technology:Watson's Generic Version of Lotrel ® Receives FDA Approval 2
... new thinking to address common problems associated ... mm diameter outer arthroscope sheath, the shorter, ... Videoscope has superior access and mobility in ... and especially in the elbow and ankle. ...
... is the second generation of the lens ... technology allows one-handed delivery of the C11UB ... colored plunger allows better visualization and is ... insertion. The modified 55-degree beveled tip eases ...
... Heart 2006 is a long-term Transtelephonic ... This device is the solution ... symptoms and their correlation to the ... it provides 2 lead loop recording ...
... cable and 4 metal chest electrodes ... 3-step procedure enabling a patient to ... lead ECG through a simple change ... seconds per lead and 10 seconds ...
Medicine Products: